title: The effect of rhBMP-2 and PRP delivery by biodegradable β-tricalcium phosphate scaffolds on new bone formation in a non-through rabbit cranial defect model.
abstract: This study evaluated whether the combination of biodegradable β-tricalcium phosphate (β-TCP) scaffolds with recombinant human bone morphogenetic protein-2 (rhBMP-2) or platelet-rich plasma (PRP) could accelerate bone formation and increase bone height using a rabbit non-through cranial bone defect model. Four non-through cylindrical bone defects with a diameter of 8-mm were surgically created on the cranium of rabbits. β-TCP scaffolds in the presence and absence of impregnated rhBMP-2 or PRP were placed into the defects. At 8 and 16 weeks after implantation, samples were dissected and fixed for analysis by microcomputed tomography and histology. Only defects with rhBMP-2 impregnated β-TCP scaffolds showed significantly enhanced bone formation compared to non-impregnated β-TCP scaffolds (P < 0.05). Although new bone was higher than adjacent bone at 8 weeks after implantation, vertical bone augmentation was not observed at 16 weeks after implantation, probably due to scaffold resorption occurring concurrently with new bone formation.
authors.affiliation: Department of Prosthodontics, Dental Science Research Institute and BK21 Project, School of Dentistry, Chonnam National University, 33 Yongbong-ro, Buk-gu, Gwangju, 500-757, South Korea.
authors.forename: Hyun-Pil
authors.initials: HP
authors.lastname: Lim
authors.forename: Angel E
authors.initials: AE
authors.lastname: Mercado-Pagan
authors.forename: Kwi-Dug
authors.initials: KD
authors.lastname: Yun
authors.forename: Seong-Soo
authors.initials: SS
authors.lastname: Kang
authors.forename: Taek-Hue
authors.initials: TH
authors.lastname: Choi
authors.forename: Julius
authors.initials: J
authors.lastname: Bishop
authors.forename: Jeong-Tae
authors.initials: JT
authors.lastname: Koh
authors.forename: William
authors.initials: W
authors.lastname: Maloney
authors.forename: Kwang-Min
authors.initials: KM
authors.lastname: Lee
authors.forename: Yunzhi Peter
authors.initials: YP
authors.lastname: Yang
authors.forename: Sang-Won
authors.initials: SW
authors.lastname: Park
mesh_terms: D020341:Absorbable Implants; D000818:Animals; D055396:Bone Morphogenetic Protein 2 / Q000008:administration & dosage / Q000494:pharmacology*; D001861:Bone Regeneration / Q000187:drug effects; D002130:Calcium Phosphates / Q000737:chemistry*; D004337:Drug Carriers / Q000138:chemical synthesis / Q000737:chemistry; D016503:Drug Delivery Systems / Q000295:instrumentation / Q000379:methods*; D006801:Humans; D008297:Male; D023421:Models, Animal; D010012:Osteogenesis / Q000187:drug effects*; D053657:Platelet-Rich Plasma / Q000502:physiology; D011817:Rabbits; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D012886:Skull / Q000293:injuries* / Q000473:pathology; D012887:Skull Fractures / Q000503:physiopathology / Q000628:therapy; D054457:Tissue Scaffolds / Q000737:chemistry*
chemical_list: C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D002130:Calcium Phosphates; D004337:Drug Carriers; D011994:Recombinant Proteins; C485817:beta-tricalcium phosphate